Document is current
Any future updates will be listed below
-
Authors
Hisaoka, Kazuhiko
Matsuda, Satoru
Kawakubo, Hirofumi
Kitagawa, Yuko
- License Information
-
More Information
Article History
Received: 8 May 2025
Accepted: 10 May 2025
First Online: 3 June 2025
Disclosure
: Yuko Kitagawa declares financial connection to: Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd, Asahi Kasei Pharma Corporation, Otsuka Pharmaceutical Co., Ltd., Tsumura and Co., Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd., Kaken Pharmaceutical Co., Ltd., Sumitomo Pharma Co., Ltd., Otsuka Pharmaceutical Factory Inc., Kyouwa Hakkou Kirin Co., Ltd., Teijin Pharma Ltd., Kowa Company, Ltd., Astrazeneca K.K., Ethicon Inc., Ono Pharmaceutical Co., Ltd., Olympus Corporation, Cardinal Health K.K., Shionogi and Co., Ltd., Bristol Myers Squibb K.K., MSD K.K., Smith and Nephew K.K., Aska Pharmaceutical Co., Ltd., Miyarisan Pharmaceutical Co., Ltd., Toray Industries, Inc., Daiichi Sankyo Company, Ltd., Chugai Foundation for Innovative Drug Discovery Science, Nippon Kayaku Co., Ltd., EA Pharma Co., Ltd., Intuitive Surgical G.K., Sysmex Corporation, AI Medical Service Inc., Joint Research Laboratory for Development and Education of Innovative Medical Technology, Sysmex Corporation, Medicaroid Corporation, and the Japanese Society of Gastroenterological Surgery Editor in Chief of Annals of Gastroenterological Surgery.
